{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:52:28Z","timestamp":1784253148012,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejphar.2021.174122","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T06:09:15Z","timestamp":1619590155000},"page":"174122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Time-dependent influence of infliximab on hemodynamic responses and cardiac injuries of isoproterenol-induced myocardial infarction in rats"],"prefix":"10.1016","volume":"903","author":[{"given":"Nasrin","family":"Maleki Dizaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Garjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Vaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174122_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4037\/ajcc1998.7.6.418","article-title":"Cardiac biomarkers: past, present, and future","volume":"7","author":"Adams","year":"1998","journal-title":"Am. J. Crit. Care"},{"key":"10.1016\/j.ejphar.2021.174122_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.297.1.43","article-title":"Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial","volume":"297","author":"Armstrong","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2021.174122_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrcardio.2015.5","article-title":"Anti-inflammatory therapies for atherosclerosis","volume":"12","author":"Back","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174122_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4236\/abb.2013.47A1004","article-title":"Association of monoctye expression of Toll-like receptor 4 and its related cytokines with coronary luminal stenosis","volume":"4","author":"Bagheri","year":"2013","journal-title":"Adv. Biosci. Biotechnol."},{"key":"10.1016\/j.ejphar.2021.174122_bib5","first-page":"149","article-title":"Monocyte expression of Toll-like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention","volume":"9","author":"Bagheri","year":"2012","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.ejphar.2021.174122_bib6","series-title":"Methods of Enzymatic Analysis","first-page":"XLIII","author":"Bergmeyer","year":"1974"},{"key":"10.1016\/j.ejphar.2021.174122_bib7","first-page":"373","article-title":"Myocytolysis and mitochondrial calcification in rat myocardium after low doses of isoproterenol","volume":"54","author":"Bloom","year":"1969","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2021.174122_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/14656566.2016.1186648","article-title":"Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review","volume":"17","author":"Boulakh","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.174122_bib9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2021.174122_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/eurheartj\/eht420","article-title":"Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial","volume":"35","author":"Cerisano","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2021.174122_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2021.174122_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.yjmcc.2009.12.013","article-title":"Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload","volume":"49","author":"Chen","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174122_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1515\/CCLM.2008.062","article-title":"Simple method for determining human serum 2,2-diphenyl-1-picryl-hydrazyl (DPPH) radical scavenging activity - possible application in clinical studies on dietary antioxidants","volume":"46","author":"Chrzczanowicz","year":"2008","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ejphar.2021.174122_bib14","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2021.174122_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0140-6736(13)60058-6","article-title":"NCDs: a challenge to sustainable human development","volume":"381","author":"Clark","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174122_bib16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/ATVBAHA.112.254409","article-title":"The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction","volume":"32","author":"Cochain","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2021.174122_bib17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2021.174122_bib18","first-page":"100","article-title":"The effect of astragaloside IV on isoproterenol-induced myocardial infarction in rats","volume":"25","author":"Fathiazad","year":"2019","journal-title":"Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2021.174122_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2011.04.061","article-title":"Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat","volume":"666","author":"Garjani","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174122_bib20","first-page":"28","article-title":"A study on the methods of estimation of LDH activity in serum","volume":"8","author":"Ghosh","year":"1963","journal-title":"Med. Exp. Int. J. Exp. Med."},{"key":"10.1016\/j.ejphar.2021.174122_bib21","first-page":"712","article-title":"Markers of oxidative stress in ICU clinical settings: present and future","volume":"10","author":"Grune","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.ejphar.2021.174122_bib22","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.86.17.6753","article-title":"Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness","volume":"86","author":"Gulick","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2021.174122_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tcm.2018.02.003","article-title":"Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure","volume":"28","author":"Hartman","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2021.174122_bib24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/bph.14155","article-title":"Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges","volume":"175","author":"Huang","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174122_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/131950","article-title":"TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice","author":"Jarr","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejphar.2021.174122_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hlc.2012.12.002","article-title":"Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure","volume":"22","author":"Javed","year":"2013","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ejphar.2021.174122_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s40199-014-0068-3","article-title":"Tacrolimus ameliorates functional disturbances and oxidative stress in isoproterenol-induced myocardial infarction","volume":"22","author":"Khorrami","year":"2014","journal-title":"Daru"},{"key":"10.1016\/j.ejphar.2021.174122_bib28","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2021.174122_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2021.174122_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.17305\/bjbms.2007.3088","article-title":"Acute heart failure after myocardial infarction","volume":"7","author":"Maci\u0107-Dzankovi\u0107","year":"2007","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.ejphar.2021.174122_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0008-6363(99)00132-7","article-title":"Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?","volume":"43","author":"Mehta","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174122_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2021.174122_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2021.174122_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","article-title":"Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities","volume":"186","author":"Ong","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.174122_bib35","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/heartjnl-2013-303648","article-title":"Cardiovascular effects of tumour necrosis factor \u03b1 antagonism in patients with acute myocardial infarction: a first in human study","volume":"99","author":"Padfield","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2021.174122_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/cvr\/cvy145","article-title":"Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition","volume":"114","author":"Panahi","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174122_bib37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174122_bib38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0002-9149(01)01723-4","article-title":"An anti-CD11\/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study)","volume":"88","author":"Rusnak","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174122_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-\u03b1 in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejphar.2021.174122_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.intimp.2012.10.014","article-title":"Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected?","volume":"14","author":"Soraya","year":"2012","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2021.174122_bib41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1253\/circj.66.627","article-title":"Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide","volume":"66","author":"Sugamori","year":"2002","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2021.174122_bib42","first-page":"137","article-title":"Oxidative stress and total antioxidant status in myocardial infarction","volume":"48","author":"Surekha","year":"2007","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.ejphar.2021.174122_bib43","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jacc.2013.03.003","article-title":"Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial","volume":"61","author":"Tardif","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174122_bib44","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI118095","article-title":"Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes","volume":"96","author":"Thaik","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2021.174122_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2015.12.030","article-title":"Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart","volume":"772","author":"Vaez","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174122_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation \u2013 cause or consequence of heart failure or both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.ejphar.2021.174122_bib47","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","article-title":"Use of oral corticosteroids and the risk of acute myocardial infarction","volume":"192","author":"Varas-Lorenzo","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2021.174122_bib48","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/bph.13818","article-title":"Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?","volume":"174","author":"Welsh","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174122_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNFalpha blockade in human diseases: mechanisms and future directions","volume":"126","author":"Wong","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2021.174122_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/CCM.0b013e31820a91b9","article-title":"Plasma levels of tumor necrosis factor-\u03b1 and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase","volume":"39","author":"Wu","year":"2011","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2021.174122_bib51","first-page":"366","article-title":"Association between activities of SOD, MDA and Na+-K+-ATPase in peripheral blood of patients with acute myocardial infarction and the complication of varying degrees of arrhythmia","author":"Yin","year":"2018","journal-title":"Hellenic J. Cardiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921002752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921002752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:49:21Z","timestamp":1757976561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921002752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"alternative-id":["S0014299921002752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174122","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-dependent influence of infliximab on hemodynamic responses and cardiac injuries of isoproterenol-induced myocardial infarction in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174122"}}